(UroToday.com) In the Proffered Paper Session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Andrew Armstrong presented the final overall survival ...
(UroToday.com) In this presentation, Dr. Fred Saad presented results of the PROpel study. PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as ...
(Urotoday.com) The newly formed Global Society of Rare Genitourinary Tumors (GSRGT) held its inaugural meeting, focusing on penile and testicular cancer. The session held Saturday, December 12 th ...
Wallace BK, Su ZT, Flynn JP, Garman TS, Weitzner A, Rezaee ME, et al. National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database. Urol ...
Andrea Necchi presents GDFATHER-NEO trial results, evaluating neoadjuvant nivolumab plus visugromab versus nivolumab-placebo in 31 cisplatin-ineligible/refusing muscle-invasive bladder cancer patients ...
Kidney stones (nephrolithiasis/urolithiasis) are a clinically significant yet underrecognized complication of autosomal dominant polycystic kidney disease (ADPKD ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...
Patients with low-grade upper tract urothelial carcinoma who achieved a complete response after receiving treatment with ...
LUGPA 2025: MIBC – What You Should Be Doing Today and What We Will Be Doing Tomorrow ...
Neeraj Agarwal: Welcome to another episode of UroToday Video. It's such an honor and a pleasure to welcome Professor Eleni Efstathiou to our program today to talk about the phase III AMPLITUDE data, ...
Dr. Lee concluded his presentation discussing the comparative performance of UNFOLD AI, PSMA-PET, and mpMRI for prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback